Views: 1,830 | Downloads:
259
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Efficacy and Safety of Enoxaparin during Hemodialysis: Results from the HENOX Study
Vareesangthip K 
,
Thitiarchakul S ,
Kanjanakul I ,
Sumethkul V ,
Krairittichai U ,
Chittinandana A ,
Bannachak D
,
Thitiarchakul S ,
Kanjanakul I ,
Sumethkul V ,
Krairittichai U ,
Chittinandana A ,
Bannachak D Background: Low molecular weight heparins (LMWHs) have been suggested as an anticoagulant in hemodialysis (HD)since they provide convenient usage, safety and effective outcomes.
Objective: Determine clinical efficacy and safety of enoxaparin sodium for the anticoagulation effect during HD in 99 clinicallystable end-stage renal disease (ESRD) patients.
Material and Method: This prospective open-label study was conducted in seven hemodialysis centers in Thailand. HDprescription during the present study was similar to the previous prescriptions including the type of dialyzer. Enoxaparinsodium 0.7 mg/kg was administered into a pre-dialyzer arterial line at the beginning of the HD session. The anticoagulationeffect was monitored by visual inspection of the HD line hourly and inspection of the dialyzer at the end of HD session.Vascular access compression time was monitored at both arterial and venous sites separately at the end of the HD.
Results: HD with enoxaparin sodium resulted in no fibrin/clot formation in a hemodialysis line in 97 cases (98%), and nosignificant clot formation in a dialyzer in 96 cases (97%). The mean vascular compression time was 5.63 + 1.90 minutes atthe arterial site and 5.72 + 2.61 minutes at the venous site. Neither major adverse events nor major hemorrhages werereported. Prolonged activated partial thromboplastin times (aPTT) at 30 minutes after hemodialysis were reported in twocases. These abnormal aPTT cases returned to normal levels within 24 hours and 72 hours, respectively.
Conclusion: The present study suggests that a single-dose regimen of enoxaparin sodium 0.7 mg/kg is an effective, welltolerated,and convenient alternative to sodium heparin.Keywords: Enoxaparin sodium, Hemodialysis, ESRD, Anticoagulant
Keywords: Enoxaparin sodium, Hemodialysis, ESRD, Anticoagulant
Objective: Determine clinical efficacy and safety of enoxaparin sodium for the anticoagulation effect during HD in 99 clinicallystable end-stage renal disease (ESRD) patients.
Material and Method: This prospective open-label study was conducted in seven hemodialysis centers in Thailand. HDprescription during the present study was similar to the previous prescriptions including the type of dialyzer. Enoxaparinsodium 0.7 mg/kg was administered into a pre-dialyzer arterial line at the beginning of the HD session. The anticoagulationeffect was monitored by visual inspection of the HD line hourly and inspection of the dialyzer at the end of HD session.Vascular access compression time was monitored at both arterial and venous sites separately at the end of the HD.
Results: HD with enoxaparin sodium resulted in no fibrin/clot formation in a hemodialysis line in 97 cases (98%), and nosignificant clot formation in a dialyzer in 96 cases (97%). The mean vascular compression time was 5.63 + 1.90 minutes atthe arterial site and 5.72 + 2.61 minutes at the venous site. Neither major adverse events nor major hemorrhages werereported. Prolonged activated partial thromboplastin times (aPTT) at 30 minutes after hemodialysis were reported in twocases. These abnormal aPTT cases returned to normal levels within 24 hours and 72 hours, respectively.
Conclusion: The present study suggests that a single-dose regimen of enoxaparin sodium 0.7 mg/kg is an effective, welltolerated,and convenient alternative to sodium heparin.Keywords: Enoxaparin sodium, Hemodialysis, ESRD, Anticoagulant
Keywords: Enoxaparin sodium, Hemodialysis, ESRD, Anticoagulant
Download:
PDF